Piper Jaffray believes the Complete Response Letter issued to Regeneron for ARCALYST to prevent gout flares was widely expected after the negative panel vote in May. The firm reiterates a Neutral rating on the stock with a $128 price target.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?